Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class.
Innocenti T, Hanžel J, Truyens M, Lukaš M, Gordon H, Cremer A, Molnár T, Julsgaard M, Onali S, Todeschini A, Nardone OM, Noor NM, Caprioli F, Scaldaferri F, Argyriou K, Savarino EV, Brinar M, Hedin CRH, Vela González M, Armuzzi A, Blesl A, Aratari A, Quadarella A, Parigi TL, Bertani L, Ferracane C, Uzzan M, Michalopoulos G, De Bernardi A, Katsanos K, Balestrieri P, Piñero G, Karmiris K, Casbas AG, Nikolic S, Felice C, Pugliese D, Pastras P, Mocci G, Pouillon L, Mantzaris GJ, Ramos L, Casanova MJ, Koutroubakis IE, García MJ; Jaki-SEQ Study Group; Lobaton T, Dragoni G.
Innocenti T, et al.
J Crohns Colitis. 2025 Nov 3:jjaf188. doi: 10.1093/ecco-jcc/jjaf188. Online ahead of print.
J Crohns Colitis. 2025.
PMID: 41183095